May 12, 2025, 09:52
Goutham Sunny: Treatment Outcomes in KMT2A-Rearranged AML
Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X:
“KMT2A-rearranged AML responds well to intensive chemo (CR/CRi 81–100%, 5-yr OS 66%), but outcomes remain poor with low-intensity treatment (CR/CRi 33–61%, OS 7%), especially with N/KRAS mutations—highlighting need for better therapies.”
More posts featuring Acute Myeloid Leukemia on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 18:30
Aug 5, 2025, 18:18
Aug 5, 2025, 18:04
Aug 5, 2025, 17:52
Aug 5, 2025, 16:29
Aug 5, 2025, 16:07
Aug 5, 2025, 16:04